Frontier drug discovery programs require frontier capabilities. Today, we’re excited to share that BMS will be using Chai’s models to support the discovery of new therapeutics. Since rolling out Chai-3 to partners at the start of this year, we’ve partnered with @EliLillyandCo, @Novartis, @Pfizer, @argenxglobal, and now @BMSnews. Many of the world’s leading biopharma companies are now using our models to go after diseases. Scientific discovery is the domain where access to frontier AI matters the most. At @ChaiDiscovery, we’ve seen first hand how our latest model generations can make the difference between discovering a molecule and not. We’re excited to work with @BMSnews to break new ground in medicine and science.

Tune in to @latentspacepod to hear @Mattmcpartlon1 and @realdealpatil talk about the transformational moment bio AI is going through, and why you don't need a background in biology to make an impact in the space.

Sometimes in academia ppl will say stuff like chai, protenix, boltz, openfold, rf3, etc. are all AF3 'clones' with an undertone around novelty, etc. I think this is such a wrong way to look at it, these models are all foundations for real products now and also importantly the journey to developing them and (as we see now) exceeding AF3 builds knowledge and understanding in the teams behind the magic! Having worked on these types of models myself recently, I found myself nodding along to Joshua here - its all really hard fought wins and compounding ablations :)

Our bet from day one: this is how most future drugs are going to be discovered. My co-founder @Mattmcpartlon1 and I sat down with @gradypb from @sequoia to talk about how drug discovery is becoming an engineering discipline

Chai Discovery cofounder @jackdent says AI drug discovery hit a major inflection point in 2025. As a result, it's now being deployed at the biggest pharma companies as part of their core discovery engines. "Over the course of 2025, these models went from being research curiosities... to being able to design molecules without needing to fine-tune them on a lot of data." "You can really just prompt them in the way that you'd prompt an LLM with a target, maybe some disease you're going after. And they will design a number of candidates that would help do that, essentially." "A year, year and a half ago, basically none of this stuff worked." "In 2025 we really crossed the Rubicon. And now these technologies are actively being deployed in companies like Eli Lilly, Novartis, Pfizer. These are some of the most scientific, highest-tech companies in the world. And they're putting them into real drug programs and making them part of their core discovery engines."

Tomorrow's medicines should be designed with the precision and scale of modern engineering. I'm thrilled that @ChaiDiscovery has raised a $400M Series C at a $3.8B valuation from @IndexVentures @KleinerPerkins @Sequoia @_DimensionCap to accelerate progress towards that goal.

"We have this long term vision of turning biology from something which is trial and error and experimental and make it something that looks more like an engineering discipline in the next century." New Episode with @jackdent ! 0:00 Intro 02:28 Inside @stripe w/ @patrickc, at <100 People 08:45 @sama role in @chaidiscovery origin 16:20 Chai-2 Antibody Breakthrough 19:24 Approaching biology as an engineering problem 24:45 Using AI models to treat people on an individual scale 26:52 Robotics in labs 27:22 Pharma industry today 29:49 The clinical trial bottleneck 32:53 Personalized biology models & cancer vaccines 36:24 Longevity, peptides, and trillion-dollar drugs 39:02 Does it matter that the government cut exploratory science grants? 41:00 What next-gen Chai models will do 42:08 Can frontier AI labs build this themselves? 43:26 Biology is hard

𝐀𝐈 𝐍𝐞𝐰𝐬: Already this year @chaidiscovery has raised a $130M series B and struck a discovery partnership with Eli Lilly - Co-Founder @jackdent describes how Chai is using AI to design antibodies. Full video:

Grateful to share the stage with @robzirk and @BenjamineYLiu at PhRMA Forum today. We are at a critical inflection point for the industry. AI deployment is taking off, and 2026 will be the year get a glimpse of how it will transform the future of medicine.

Really enjoyed this @corememory conversation with @ashleevance. We dug into an important question: can AI actually do scientific discovery, or does it just speed up human intuition? Watching models design molecules we wouldn’t reasonably arrive at has been remarkable

.@chaidiscovery raised a Series B just three months after their Series A, and we co-led it. GC's Elena Viboch recently joined @Bloomberg's @CarolineHydeTV alongside Chai Discovery co-founder @joshim5 to discuss our life sciences investment strategy and the breakthrough technology behind Chai Discovery. We believe 2026 will be the year of deployment for AI in pharma. Chai Discovery’s latest model, Chai-2, has achieved an 85% success rate in computationally designing molecules that meet drug-like properties. In our view, pharmaceutical companies that adopt this technology will leapfrog those who do not. We partner with companies like Chai Discovery to turn known biology and impossible chemistry into lifesaving treatments. Why we invested → More on our life sciences thesis →